PURPOSE OF THE REPORT: F-FDG PET is limited for assessment of central nervous system lymphoma (CNSL) due to physiologic tracer accumulation in the brain. We prospectively evaluated the novel PET tracer Ga-pentixafor, which targets the C-X-C chemokine receptor 4 (CXCR4), for lesion visualization and response assessment of CNSL. MATERIALS AND METHODS: Seven CNSL patients underwent Ga-pentixafor PET/MRI with contrast enhancement (CE-MRI) and diffusion-weighted sequences. The accuracy of Ga-pentixafor PET for CNSL lesion detection relative to the CE-MRI reference standard was determined. Standardized uptake values (SUVmean and SUVmax), PET-based (PTV) and MRI-based (VOLMRI) tumor volumes, and apparent diffusion coefficients (ADCs) were assessed, and correlation coefficients were calculated. Three SUVmax thresholds (41%, 50%, and 70%) were evaluated for PTV definitions (PTV41%, PTV50%, and PTV70%) and tested against VOLMRI using paired sample t tests. RESULTS: Twelve Ga-pentixafor PET/MRI examinations (including 5 follow-up scans) of 7 patients were evaluated. Ga-pentixafor PET demonstrated 18 lesions, all of which were confirmed by CE-MRI; there were no false-positive lesions on PET (accuracy, 100%). PTV41% showed the highest concordance with lesion morphology, with no significant difference compared with VOLMRI (mean difference, -0.24 cm; P = 0.45). The correlation between ADCmean and SUVmean41% (r = 0.68) was moderate. Changes in PTV41% on follow-up PET/MRI showed the same trend as VOLMRI changes, including progression of 1 lesion each in patient 1 (+456.0% PTV41% and +350.8% VOLMRI) and patient 3 (+110.4% PTV41% and +85.1% VOLMRI). CONCLUSIONS: Ga-pentixafor PET may be feasible for assessment and follow-up of CNSL. Future studies need to focus on testing its clinical value to distinguish between glioma and CNSL, and between radiation-induced inflammation and viable residual tumor.
PURPOSE OF THE REPORT: F-FDG PET is limited for assessment of central nervous system lymphoma (CNSL) due to physiologic tracer accumulation in the brain. We prospectively evaluated the novel PET tracer Ga-pentixafor, which targets the C-X-C chemokine receptor 4 (CXCR4), for lesion visualization and response assessment of CNSL. MATERIALS AND METHODS: Seven CNSL patients underwent Ga-pentixafor PET/MRI with contrast enhancement (CE-MRI) and diffusion-weighted sequences. The accuracy of Ga-pentixafor PET for CNSL lesion detection relative to the CE-MRI reference standard was determined. Standardized uptake values (SUVmean and SUVmax), PET-based (PTV) and MRI-based (VOLMRI) tumor volumes, and apparent diffusion coefficients (ADCs) were assessed, and correlation coefficients were calculated. Three SUVmax thresholds (41%, 50%, and 70%) were evaluated for PTV definitions (PTV41%, PTV50%, and PTV70%) and tested against VOLMRI using paired sample t tests. RESULTS: Twelve Ga-pentixafor PET/MRI examinations (including 5 follow-up scans) of 7 patients were evaluated. Ga-pentixafor PET demonstrated 18 lesions, all of which were confirmed by CE-MRI; there were no false-positive lesions on PET (accuracy, 100%). PTV41% showed the highest concordance with lesion morphology, with no significant difference compared with VOLMRI (mean difference, -0.24 cm; P = 0.45). The correlation between ADCmean and SUVmean41% (r = 0.68) was moderate. Changes in PTV41% on follow-up PET/MRI showed the same trend as VOLMRI changes, including progression of 1 lesion each in patient 1 (+456.0% PTV41% and +350.8% VOLMRI) and patient 3 (+110.4% PTV41% and +85.1% VOLMRI). CONCLUSIONS: Ga-pentixafor PET may be feasible for assessment and follow-up of CNSL. Future studies need to focus on testing its clinical value to distinguish between glioma and CNSL, and between radiation-induced inflammation and viable residual tumor.
Authors: Marius E Mayerhoefer; Ulrich Jaeger; Philipp Staber; Markus Raderer; Wolfgang Wadsak; Sarah Pfaff; Christoph Kornauth; Daniela Senn; Michael Weber; Hans-Juergen Wester; Cathrin Skrabs; Alexander Haug Journal: Invest Radiol Date: 2018-07 Impact factor: 6.016
Authors: Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister Journal: J Clin Oncol Date: 2014-09-20 Impact factor: 44.544
Authors: Andrés J M Ferreri; Kate Cwynarski; Elisa Pulczynski; Maurilio Ponzoni; Martina Deckert; Letterio S Politi; Valter Torri; Christopher P Fox; Paul La Rosée; Elisabeth Schorb; Achille Ambrosetti; Alexander Roth; Claire Hemmaway; Angela Ferrari; Kim M Linton; Roberta Rudà; Mascha Binder; Tobias Pukrop; Monica Balzarotti; Alberto Fabbri; Peter Johnson; Jette Sønderskov Gørløv; Georg Hess; Jens Panse; Francesco Pisani; Alessandra Tucci; Stephan Stilgenbauer; Bernd Hertenstein; Ulrich Keller; Stefan W Krause; Alessandro Levis; Hans J Schmoll; Franco Cavalli; Jürgen Finke; Michele Reni; Emanuele Zucca; Gerald Illerhaus Journal: Lancet Haematol Date: 2016-04-06 Impact factor: 18.959
Authors: Peter Herhaus; Jana Lipkova; Felicitas Lammer; Igor Yakushev; Tibor Vag; Julia Slotta-Huspenina; Stefan Habringer; Constantin Lapa; Tobias Pukrop; Dirk Hellwig; Benedikt Wiestler; Andreas K Buck; Martina Deckert; Hans-Jürgen Wester; Florian Bassermann; Markus Schwaiger; Wolfgang Weber; Björn Menze; Ulrich Keller Journal: J Nucl Med Date: 2020-04-24 Impact factor: 10.057
Authors: Constantin Lapa; Katharina Lückerath; Irene Kleinlein; Camelia Maria Monoranu; Thomas Linsenmann; Almuth F Kessler; Martina Rudelius; Saskia Kropf; Andreas K Buck; Ralf-Ingo Ernestus; Hans-Jürgen Wester; Mario Löhr; Ken Herrmann Journal: Theranostics Date: 2016-01-25 Impact factor: 11.556
Authors: Constantin Lapa; Martin Schreder; Andreas Schirbel; Samuel Samnick; Klaus Martin Kortüm; Ken Herrmann; Saskia Kropf; Herrmann Einsele; Andreas K Buck; Hans-Jürgen Wester; Stefan Knop; Katharina Lückerath Journal: Theranostics Date: 2017-01-01 Impact factor: 11.556
Authors: Alexander R Haug; Asha Leisser; Wolfgang Wadsak; Markus Mitterhauser; Sarah Pfaff; S Kropf; Hans-Juergen Wester; Marcus Hacker; Markus Hartenbach; Barbara Kiesewetter-Wiederkehr; Markus Raderer; Marius E Mayerhoefer Journal: Theranostics Date: 2019-05-27 Impact factor: 11.556